Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphomaPoster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphomaLAUSANNE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug ...

Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC ProgramsNovember 04, 2024 6:15 PM EST | Source: Defence Therapeutics Inc.Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in additi ...

LAUSANNE, Switzerland, Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November:Guggenheim Securities Healthcare Innovation ConferenceDate: November 11, 2024Presentation Time: 11:00 a.m. ETFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerJefferies London Healthcare ConferenceDate: November 19, 2024Presentation Time: 11:00 ...

Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global sales of ADCs on the market are showing a rapid growth trend, with growth rates of 36.5% and 40.7% in 2022 and 2023, respectively, with the market reaching a value of $10.8 billion in 2023. The market is projected to grow to more than $47 billion by the end of 2029, with a robust projected CAGR of 28.4% during the forecast period. T ...

LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North Amer ...

I like net lease REITs and as Agree Realty (NYSE: ADC ) is one of the largest net lease REITs out there, I am keeping an eye on the stock and its preferred shares. As it has been He is the leader of the investment group European Small Cap Ideas which offers exclusive access to actionable research on appealing Europe-focused investment opportunities not found elsewhere. The a focus is on highquality ideas in the small-cap space, with emphasis on capital gains and dividend income for continuous cash flow. Fea ...

You won't be charged a penny during the free trial, so you have nothing to lose and everything to gain. If you want full access to our Portfolio and all our current Top Picks, feel free to join us at High Yield Landlord for a 2-week free trial. REITs have been surging on the prospects of rate cuts, but we think that they are likely to surge a lot higher in the coming years He is the leader of the investing group High Yield Landlord , where he shares his real-money REIT portfolio and transactions in real-tim ...

My followers already know well I am on the hunt for superior total return investments, with my eyes set on accumulating a large nest egg, taking advantage of compounding while I can, rather than focusing on immediate income-paying investments. However, I also find myself often With 30 years until retirement, I'm leveraging my role as a Financial Analyst at a Fortune 500 firm to build a market-beating portfolio that targets both strong capital appreciation and aggressive dividend growth.My focus is on blue-c ...

Analyst's Disclosure: I/we have a beneficial long position in the shares of RIET, HOMZ, IRET, ALL HOLDINGS IN THE IREIT+HOYA PORTFOLIOS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Hoya Capital Research & Index Innovations ("Hoya Capital") is an affiliate of Hoya Capi ...

ROYAL OAK, Mich., Oct. 24, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the pricing of its public offering of 4,400,000 shares of its common stock at a public offering price of $74.00 per share in connection with the forward sale agreements described below. The Company also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock. The offering was upsized from the previously announced offering size of 4,000,000 share ...